The Food and Drug Administration (FDA) recently approved Voquezna, a new daily treatment for heartburn associated with non-erosive gastroesophageal reflux disease (GERD) in adults. GERD is a condition in which stomach acid flows backward into the esophagus, causing symptoms such as heartburn. Non-erosive GERD, also known as NERD, does not damage the lining of the esophagus, but can still lead to discomfort.
Voquezna, developed by Phathom Pharmaceuticals, is a small-molecule potassium-competitive acid blocker (PCAB) that works by blocking the secretion of acid in the stomach. In a phase 3 clinical trial, Voquezna was found to significantly reduce heartburn episodes in adults with non-erosive GERD. The medication has also been approved for treating erosive esophagitis and Helicobacter pylori infection in combination with antibiotics.
The most common side effects reported by patients taking Voquezna were abdominal pain, constipation, diarrhea, nausea, and urinary tract infection. Some participants in a 20-week extension phase of the trial also experienced upper respiratory tract infection and sinusitis.
While Voquezna offers a new option for individuals with non-erosive GERD, some caution has been advised regarding potential long-term side effects. Similar to proton pump inhibitors, Voquezna may increase the risk of bone fracture, kidney disease, or nutrient deficiencies with prolonged use. Gastroenterologists suggest that individuals should be mindful of these risks and consult with their healthcare providers before starting any new medication.
Overall, the approval of Voquezna provides physicians with an alternative treatment for heartburn associated with GERD, offering relief for individuals who may not respond well to traditional proton pump inhibitors. The medication's ability to start faster and last longer than existing treatments may improve the quality of life for those with non-erosive GERD, providing a new tool in managing this common condition.